Markets
BUSINESS NEWS
- Market News
- Earnings
- Recalls
- Recession Watch
- Tech News
- Financial Crisis
- Madoff Scandal
- BloggingStocks
- Luxist
- Money Videos
INVESTING
- Stock Quotes
- Stock Charts
- Stock Ticker
- Currencies
- Portfolio
- Stock Screener
- Broker Center
- Mutual Fund Center
- ETF Center
- Money
- 24/7 Wall St.
- Financial Glossary
PERSONAL FINANCE AT WALLETPOP
- Bargains
- Banking
- Budget
- Calculators
- College Finance
- Community
- Credit
- Deals
- Debt
- Economizer
- Food
- Home
- Fraud
- Insurance
- Interest Rates
- Loans
- Mortgages
- Real Estate
- Recalls
- Recession
- Retirement
- Saving
- Simplification
- Specials
- Taxes
SMALL BUSINESS
Cypress Bioscience, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference
SAN DIEGO, CA -- (Marketwire) -- 10/30/09 -- Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at the Oppenheimer 20th Annual Healthcare Conference on November 3, 2009.
The Oppenheimer conference is being held at the Waldorf=Astoria Hotel in New York, NY. Ms. Johnson is scheduled to present on Tuesday, November 3rd at 1:00 p.m. Eastern Time. The audio broadcast of this presentation can be accessed at http://www.veracast.com/webcasts/opco/healthcare09/85108244.cfm.
A replay of the presentation will be available at the same web address as well as on Cypress' website, http://www.cypressbio.com/events.php.
About Cypress Bioscience
Cypress Bioscience, Inc. provides therapeutics and personalized medicine services, facilitating improved and individualized patient care. Cypress addresses the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders such as fibromyalgia and rheumatoid arthritis. This approach to improving patient care creates a unique partnership with physicians. Current products include Savella® (milnacipran HCI) and the Avise PG(SM) and Avise MCV(SM) therapeutic monitoring, diagnostic and prognostic tests for rheumatoid arthritis.
For more information about Cypress, please visit the Company's website at www.cypressbio.com.
For additional information please contact
Mary Gieson
Investor Relations
(858) 452-2323
Email Contact